Clinical trial
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
NCT04074993
Study timeline
Study start (actual)2020-05-15Date precision: day
Registry last updated2023-09-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non Small Cell Lung Cancerunresolved
Interventions
BrigatinibDRUG · verified · RxNorm: brigatinib
Sponsors & collaborators
JI-YOUN HANlead sponsor
Seoul National University Hospitalcollaborator
Severance Hospitalcollaborator
Seoul National University Bundang Hospitalcollaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04074993 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.